FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound comprising a mutant KRAS sequence and a lipid, wherein the mutant KRAS sequence is conjugated to the lipid by a linker, and (i) the linker includes one or more polyethylene glycol blocks, (ii) the lipid is 1,2-distearoyl-sn-glycero -3-phosphoethanolamine (DSPE), and (iii) the mutant KRAS sequence consists of an amino acid sequence selected from the group consisting of the following SEQ ID NO: 1–7 and 22–30.
EFFECT: obtaining a composition including one or more of the above compounds, a method of treating cancer, and a kit for treating cancer expressing mutant KRAS.
43 cl, 7 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CPG AMPHIPHILES AND APPLICATIONS THEREOF | 2019 |
|
RU2823677C2 |
| NEO-ANTIGEN COMPOSITIONS AND USE THEREOF | 2020 |
|
RU2832574C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| FUSION CONSTRUCTION CONTAINING CELL PENETRATING PEPTIDE, POLYEPITOPE AND TLR PEPTIDE AGONIST, INTENDED FOR TREATMENT OF CANCER | 2017 |
|
RU2807135C2 |
| NEOANTIGENS AND THEIR APPLICATION | 2019 |
|
RU2805196C2 |
| Cys80-CONJUGATED IMMUNOGLOBULINS | 2016 |
|
RU2756101C2 |
| DIRECTED REGENERATION OF BROKEN BONE BY MEANS OF STIMULATION OF PARATHYROID HORMONE RECEPTOR | 2017 |
|
RU2785401C2 |
| ANTIGENIC POLYPEPTIDES BASED ON THE RESPIRATORY SYNCYTIAL VIRUS SEQUENCE | 2019 |
|
RU2807992C2 |
| COMPOSITIONS AND METHODS OF PRODUCING T-CELL COMPOSITIONS AND USE THEREOF | 2020 |
|
RU2835034C2 |
| FIMH ESCHERICHIA COLI MUTANTS AND USE THEREOF | 2021 |
|
RU2831010C1 |
